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Abstract The scorpion toxin peptide BeKm-1 was synthesised
by £uorenylmethoxycarbonyl solid phase chemistry and folded
by air oxidation. The peptide’s e¡ects on heterologous human
ether-a-go-go-related gene potassium current (IHERG) in
HEK293 cells were assessed using ‘whole-cell’ patch clamp.
Blockade of IHERG by BeKm-1 was concentration-dependent,
temperature-dependent, and rapid in onset and reversibility.
Blockade also exhibited inverse voltage dependence, inverse de-
pendence on duration of depolarisation, and reverse use- and
frequency-dependence. Blockade by BeKm-1 and recombinant
ergtoxin, another scorpion toxin known to block HERG, dif-
fered in their recovery from HERG current inactivation elicited
by strong depolarisation and in their ability to block HERG
when the channels were already activated. We conclude that
synthetic BeKm-1 toxin blocks HERG preferentially through
a closed (resting) state channel blockade mechanism, although
some open channel blockade also occurs.
/ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
An understanding of human ether-a-go-go-related gene
(HERG) potassium (Kþ) channel blockade by drugs is critical
because of its link to acquired long QT syndrome [1,2]. In an
e¡ort to understand how HERG blockade relates to cardio-
toxic risk, the mechanism of blockade has been elucidated for
a growing number of HERG blocking agents, in terms of
both molecular determinants and state dependence of block-
ade. Virtually all of the drugs for which relevant mechanistic
information is available are open/inactivated channel blockers
[3], and most are also thought to access the site of blockade
from inside the cell (e.g. [4,5]). Presumably, these drugs (which
are small molecules) can cross the plasma membrane in an
uncharged state, and when the channel is open, these drugs
can access their site of action inside the HERG channel ves-
tibule from the cytoplasmic side of the channel [6]. Recent
structural data on Kþ channels suggest that the selectivity
¢lter at the extracellular side of such channels is too small
to allow drugs to pass through to the channel vestibule,
whereas the vestibule would be more accessible from the cy-
toplasmic side of the channel, although this access could occur
only when the channel is open [7^9].
Compared to other HERG blockers (i.e. small molecules
and drugs), the two known scorpion toxin peptides that po-
tently block HERG are unusual in that they are thought to
act from the extracellular side of the membrane. One such
toxin, ergtoxin from Centruroides noxius, has been shown to
have molecular determinants of blockade in the extracellular
S5-pore linker region, also called the ‘turret’ [10,11]. Another
such toxin, BeKm-1 from the scorpion Buthus eupeus, has
been shown, at room temperature, to block M-like currents
from NG108-15 mouse neuroblastomaUrat glioma cells and
heterologous HERG currents in human embryonic kidney
(HEK293) cells and in Xenopus oocytes [12^14].
Since the positively charged, 36 amino acid BeKm-1 peptide
is unlikely to cross the plasma membrane easily, it probably
does not access its site of action from inside the cell, and as
such BeKm-1 may also di¡er in its state dependence of block-
ade from other HERG blockers. Relatively little is known
about the channel ‘state dependence’ of the BeKm-1 peptide’s
action on HERG. Therefore, we have used £uorenylmeth-
oxycarbonyl (Fmoc) chemistry and air oxidation to synthesise
successfully an active BeKm-1 peptide, and we report this
method here. In addition, we have addressed the de¢cit in
information on BeKm-1’s state dependence of blockade, par-
ticularly in its actions at 37‡C, because HERG’s conductance
and kinetics (and those of its homologues) at 37‡C di¡er
dramatically from these properties at room temperature
[15,16]. We present evidence for a primarily closed (resting)
state-dependent blockade of HERG, demonstrated by an in-
verse voltage dependence, negative time dependence, and re-
verse use and frequency dependence (e.g. [17]).
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2. Materials and methods
2.1. Cells and electrophysiology
The HEK293 cell line stably expressing HERG (generously donated
by Professor Craig January, University of Wisconsin [15]), its main-
tenance, electrophysiological recording and conditions (including Ty-
rode superfusate and Kþ-based pipette solution), as well as methods
for capacitance and series resistance compensation, the experimental
apparatus, data acquisition, digitisation and analysis (including for-
mulae for fractional block, Hill ¢t, and Boltzmann ¢t) have been
described in detail previously [18]. This cell line is commonly used
in the assay of drug blocking e¡ects on HERG (e.g. [19]), and its
endogenous transient outward current on repolarisation to 340 mV
(the voltage where tail currents are assayed in this study) is negligible
[15,20]. On achieving whole-cell con¢guration, su⁄cient time was al-
lowed to elapse to negate the e¡ect of any time-dependent changes in
half-maximal activation voltage (V0:5) that can be observed with this
cell line. All experiments were performed at 37‡C with the exception
of concentration^response experiments that were also conducted at
room temperature.
2.2. Data analysis and presentation
Data are presented as meanSS.E.M. with the exception of IC50,
which is shown as mean plus 95% con¢dence intervals (CI). Statistical
comparisons were made using either a paired or unpaired two-tailed
Student’s t-test, a one-way analysis of variance (ANOVA) with a
Bonferroni post-test using Prism 3 software (Graphpad) or two-way
ANOVA using Intercooled Stata 7 (Stata, College Station, TX, USA).
P values of less than 0.05 were taken as statistically signi¢cant.
2.3. Drugs
In house Fmoc-synthesised BeKm-1 (referred to as BeKm-1
throughout the remaining text) and commercially available recombi-
nant BeKm-1 toxin (rBeKm-1, Alomone, Israel) and recombinant
ergtoxin (Alomone) were dissolved in sterile 10 mM Tris^HCl,
1 mM EDTA, pH 7.6 to produce stock solutions of 25 WM. Stock
solutions were aliquoted into glass vials and stored at 320‡C until
use. Stock solutions were added to normal Tyrode’s solution to make
up the concentrations referred to in Section 3. Solutions containing
drug were made up fresh each experimental day and applied via a
rapid solution delivery system [21].
2.4. Spectroscopy
Circular dichroism spectra were obtained at 20‡C using a Jobin-
Yvon CD6 spectropolarimeter, in H2O at pH 4.5 at a concentration
of 0.1 mg/ml in 0.2 cm path-length quartz cuvettes. Spectra are aver-
ages of ¢ve scans with peptide-free blanks subtracted. High resolution
nuclear magnetic resonance (NMR) spectra (2 mM peptide concen-
tration; pH 4.5) were obtained on the Jeol Alpha-500 NMR spec-
trometer of the Bristol Centre for Molecular Recognition. NMR ac-
quisition and spectral assignment methods were similar to those
described previously [22].
3. Results and discussion
3.1. Chemical synthesis, folding and characterisation of
scorpion toxin peptide BeKm-1
The polypeptide was synthesised within the Protein and
DNA facility of the Bristol Centre for Molecular Recognition
using Fmoc chemistry. This is a new method for obtaining
BeKm-1, as all previous work has used either bacterial over-
expression [13,23] or direct puri¢cation from the crude scor-
pion venom [12]. The linear peptide was puri¢ed by high per-
formance liquid chromatography (HPLC), using a linear
gradient of acetonitrile in water containing 0.1% tri£uoroace-
tic acid, using methods described previously [24,25]. The pu-
ri¢ed linear peptide was characterised by mass spectrometry,
and was air-oxidised at room temperature in the dark by
dissolving (at a concentration of 1 mg/ml) in 50 mM Tris^
HCl, 1 mM EDTA (pH 9.0), which was thoroughly pre-aer-
ated by shaking before dissolving the peptide [25]. The peptide
was fully converted within 48 h to a single species that eluted
from the HPLC column at a lower acetonitrile concentration
than the non-oxidised peptide (i.e. more polar, which is con-
sistent with the burial of hydrophobic side chains). The oxi-
dised peptide was repuri¢ed by HPLC using the same condi-
tions as for the reduced peptide (overall ¢nal yield from all
puri¢cation and preparation steps wasV10 mg per 100 mg of
crude synthetic peptide).
Oxidation of BeKm-1 was accompanied by the adoption of
secondary structure (particularly L-structure; see Fig. 1A),
consistent with this class of disulphide-bonded toxins (e.g.
maurotoxin [26] ; HsTX1 [27]). The circular dichroism spec-
trum of the oxidised peptide is very similar to the spectrum
recently reported for a recombinant version of BeKm-1 [23],
with a minimum ellipticity near 217 nm, having a value of
V313 000 deg cm2/dmol. Although the peptide did not run
well on the MALDI mass spectrometer, oxidation of the re-
duced peptide resulted in a shift in apparent molecular mass
from 4099 to 4094 mass units (expected molecular masses of
4098 and 4092 [13] for the reduced and oxidised peptides,
respectively). Con¢rmation of the correct (native) disulphide
bridge pattern, overall conformation and peptide purity was
determined by assignment of the high resolution NMR spec-
trum of the oxidised peptide (at 500 MHz). Fig. 1B illustrates
the CHK CHL region of the double quantum ¢ltered correla-
tion spectroscopy (DQF-COSY) spectrum of synthetic, oxi-
dised BeKm-1, in which correlation signals for every amino
residue are resolved. A single set of signals is observed, indi-
cating a single structural and conformational isomer. The
chemical shifts of NH, CHK and CHL protons are the same
(within 0.1 ppm) as the values deposited (BioMagRes Bank;
accession number 5184) for the toxin produced in Escherichia
coli [23]. These results con¢rm that air oxidation of the syn-
thetic BeKm-1 linear peptide, under the conditions described,
results in the native disulphide bond arrangement and overall
native fold, and yields a peptide that is equivalent to that
produced by bacterial over-expression. This may provide a
useful tool to allow large-scale production of BeKm-1 for
comprehensive pharmacological characterisation and use.
3.2. BeKm-1 toxin potency of IHERG blockade varies with
pre-pulse duration and temperature
Fig. 2A highlights the rapidity and reversibility with which
synthetic BeKm-1 block of HERG tail current (IHERG) oc-
curred. Fig. 2A shows representative current records in the
absence, presence and following wash-out of 50 nM BeKm-
1, whilst in Fig. 2B tail current amplitude for the same experi-
ment is plotted as a function of pulse number. The potency of
blockade observed under these conditions was substantially
less than the BeKm-1 potency previously reported using mam-
malian cells at room temperature in response to a 400 ms
depolarising pulse (IC50 = 3.3 nM [13]). Fig. 2C shows that
the e¡ect of BeKm-1 at steady state on IHERG tails elicited
following 2000 ms and 400 ms depolarising pulses was greater
with the shorter duration test pulse. The leftward shift of the
concentration^response relationships for IHERG tail fractional
block for the shorter depolarisation (IC50 and Hill coe⁄cient
(h) unpaired t-test, P6 0.0001 and P=0.79, respectively) sug-
gests that an attenuation of IHERG block occurred with in-
creasing time at +20 mV. Similar experiments were performed
at room temperature (n=4^11 cells at each concentration),
resulting in lower IC50 values. For 2000 ms and 400 ms de-
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polarisations, respectively, the IC50 values at room temper-
ature were 9.7 nM (CI 7.2^13.0 nM) and 7.6 nM (CI 7.2^
8.1 nM) and the Hill coe⁄cients were 1.1 S 0.1 and
1.1S 0.02 (the IC50 values are signi¢cantly di¡erent from
one another, P6 0.05). At lower temperatures HERG gating
kinetics will be slowed. Thus, temperature sensitivity of
BeKm-1 blockade may be evidence for a gating process asso-
ciated with depolarisation that relieves block.
To con¢rm the equivalence between the synthetic and re-
combinant BeKm-1, experiments identical to that reported in
Fig. 2C were performed at 37‡C using the commercially avail-
able rBeKm-1. rBeKm-1 inhibition of IHERG tails (elicited at
340 mV) yielded IC50s of 14.1 nM (CI 8.8^22.6 nM, t-test,
Ps 0.7 compared with BeKm-1) and 55.6 nM (CI 34.3^90.1
nM, t-test, Ps 0.53 compared with BeKm-1) following an
activating pulse to +20 mV for 400 or 2000 ms respectively
(n=4^11 cells at each of the six concentrations tested). Hill
coe⁄cients were also not statistically di¡erent when compared
with the respective BeKm-1 concentration^response data (t-
test, Ps 0.4). rBeKm-1 also showed qualitatively similar tem-
perature dependence of block (data not shown).
Additional time dependence experiments were performed at
37‡C using the better characterised, but structurally dissimilar
peptide HERG blocker, ergtoxin (10 nM). Similar to BeKm-1,
fractional block was signi¢cantly decreased following a longer
pre-pulse duration (2000 ms: 0.47 S 0.02 and 400 ms: 0.65S
0.02, n=3; paired t-test, P6 0.002).
3.3. Time-dependent blockade of IHERG by BeKm-1 toxin
In order to study the time course of IHERG blockade by
BeKm-1, cells were held at 3100 mV (at which all channels
would be expected to be in the closed/resting state) and then
subjected to a ‘short depolarisation’ (+40 mV for 10 ms) be-
fore IHERG tails were observed at 340 mV. The elicited cur-
rents were compared in the absence and presence (¢rst sweep)
of BeKm-1 (25 nM); representative currents are shown in Fig.
2D. By observing the ¢rst tail current elicited in the presence
of the toxin, this approach can detect (but not distinguish
between) closed-state and extremely rapid (6 10 ms) open-
state block ^ note that concentration-response measurements
in Fig. 2C are based on measurements of steady-state block-
ade. Fractional block of IHERG tail current during the proto-
col shown in Fig. 2D is 0.83S 0.03 (n=6) (cf. 0.60 S 0.02
following a 400 ms depolarising step). This is concordant
with a closed-state blocking mechanism (or an extremely rapid
open-state mechanism).
IHERG blockade by open-channel blocking class III metha-
nesulphonanilide agents during a sustained depolarisation
shows a characteristic pro¢le; it begins with virtually no
blockade initially (i.e. for 1 s) and this progressively develops
and increases over seconds during the maintained depolarisa-
tion [20,28]. In contrast, Fig. 2E shows that for BeKm-1 there
is a time-dependent relief of fractional block during the ¢rst
V4 s of a sustained depolarising pulse (10 s) to 0 mV, from
an initially high level to a lower steady-state level. Similar
observations were made in three cells with rBeKm-1 (data
not shown). A similar time-dependent relief of blockade by
BeKm-1 was also found when using a stably transfected
HERG-expressing cell line based on CHO cells that lack en-
dogenous outward currents (n=4 cells). Fig. 2F shows mean
IHERG fractional block data from Fig. 2E by BeKm-1 plotted
at 100 ms intervals during the applied voltage pulse. A clear
time-dependent relief of block is evident (ANOVA,
P6 0.0001, n=6 cells). Comparative ‘long-pulse’ experiments
using 10 nM ergtoxin are also shown in Fig. 2F. Similar to
BeKm-1, with a sustained depolarisation to 0 mV, a time-de-
pendent relief of ergtoxin block was observed (ANOVA,
Fig. 1. Circular dichroism and NMR spectra of synthetic BeKm-1.
A: Far UV circular dichroism spectra of puri¢ed synthetic BeKm-1
in H2O at pH 4.5. The dotted and heavy lines correspond to spectra
of the unoxidised (linear) peptide and the air-oxidised peptide, re-
spectively. The units are molar ellipticity per residue. B: Region of
the phase-sensitive DQF-COSY of air-oxidised BeKm-1 (in D2O at
pH* 4.5), with annotated cross-peaks correlating CHK and CHL
protons (and CHL-CHQ protons of Thr).
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P6 0.0001). However, the time course with which this oc-
curred was substantially slower (single-exponential dissocia-
tion rate constant (Koff ) at 0 mV 652.6 S 29.0 ms31 for erg-
toxin compared with 134.8S 14.7 ms31 for BeKm-1, t-test,
P6 0.00001).
3.4. Voltage-dependent block of IHERG by BeKm-1
The e¡ect of test voltage (between 340 and +50 mV) on
IHERG tail current blockade by BeKm-1 was determined using
the protocol illustrated in the upper panel of Fig. 3A. Mean
data in panel A were ¢tted by a Boltzmann equation yielding
a half-maximal activation (V0:5 ; control 320.2S 1.0 mV com-
pared with BeKm-1 318.5 S 2.8 mV, unpaired t-test, P=0.55)
and slope factor (k ; control 6.2 S 0.8 mV compared with
BeKm-1 13.4S 1.8 mV, unpaired t-test, P6 0.0005). The
likely reason the k values are doubled in BeKm-1 is that,
whilst in control IHERG tails reached a plateau between 0
and +40 mV, in the presence of BeKm-1 IHERG tail magnitude
Fig. 2. Concentration- and time-dependent inhibition of HERG tail currents (IHERG). A: Three concatenated current traces recorded from a
typical cell at 37‡C in the absence (left), presence (centre) and following washout (right) of 50 nM BeKm-1; voltage protocol (upper panel) was
applied with a start-to-start (S-to-S) interval of 12 s. B: Summary of the tail current amplitude for the cell in A. Application of 50 nM BeKm-
1 is indicated by the solid bar (typical of ¢ve cells). C: Mean fractional block data of IHERG tails (plotted as a function of BeKm-1 concentra-
tion) resulting from command protocols at 37‡C identical to that in A (2000 ms) and a similar protocol in which the depolarising step duration
was shortened to 400 ms (S-to-S intervals of 12 and 10.4 s respectively to ensure similar durations spent at 380 mV). Data are ¢tted by a Hill
equation (solid, intermittent lines). Symbols and solid lines, IC50 and h denote Fmoc-synthesised BeKm-1 data, intermittent line (no symbols
shown) denotes concentration^response curves for rBeKm-1 using protocols and conditions identical to those used for BeKm-1. D: Representa-
tive tail current records (measured at 340 mV) following a 10 ms step to +40 mV in the absence and the ¢rst current trace following equilibra-
tion in 25 nM BeKm-1 (S-to-S interval = 12 s). During equilibration cells were held for 3 min at 3100 mV to maintain channels in the closed
state. E: Typical ‘long pulse’ current traces. The cell was repeatedly stepped to zero for 10 s from a holding potential of 380 mV (lower trace)
to evoke stable steady-state currents (upper trace). Stimulation was then terminated and the cell was equilibrated in 25 nM BeKm-1 for s 3
min whilst being held at 380 mV. The cell was then subjected to the same voltage command. Traces immediately prior to and the ¢rst step fol-
lowing equilibration in BeKm-1 are shown. Plotted on the same time axis is fractional block (right ordinate axis). F: Mean data ( S S.E.M.)
for the experiment in E (n=6 cells). Time zero coincides with the voltage step from 380 mV to 0. For comparison identical experiments were
performed using 10 nM ergtoxin. Mean data ( S S.E.M.) for four cells are shown. Note that the initial rise in fractional block (which is not sig-
ni¢cant for either BeKm-1 or ergtoxin, ANOVA, Ps 0.05) may correspond to the initial endogenous to heterologous current ratio diminishing
over time.
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tended to increase (relatively) over this potential range as
block was reduced. Fig. 3B shows the tail current fractional
block data plotted as a function of test potential. An inverse
voltage dependence was observed (ANOVA, P6 0.0001). In-
verse voltage dependence is concordant with closed state-de-
pendent blockade. However this alone is not su⁄cient to
prove closed-state blockade, as a HERG blockade attenuated
by inactivation would also demonstrate inverse voltage depen-
dence.
Diminished block with both increasing time and membrane
potential may re£ect an in£uence of channel inactivation upon
BeKm-1’s action. The potential role of inactivation was ad-
dressed further by depolarising HERG to a very positive po-
tential (invoking profound inactivation) to determine whether
or not IHERG blockade was altered. Fig. 3C shows a modi¢ed
long-pulse protocol, in which a 4 s depolarisation to +80 mV
was applied from 0 [20,29,30]. Mean fractional block data
from six cells tested as in Fig. 3C are plotted at 100 ms
intervals in Fig. 3D. Depolarisation to +80 mV further re-
duced fractional block, approximating towards zero as the
control and BeKm-1 currents converge. On repolarisation to
0, block can be seen to re-develop over time back to a level
similar to that observed at the end of the protocol in Fig. 2F
(intermittent line shown here has been redrawn from Fig. 2F),
which is a 10s depolarising pulse to 0 mV lacking the inter-
posed step to +80 mV. At +80 mV the preponderance of
Fig. 3. Voltage-dependent block of IHERG by BeKm-1. A: Mean IHERG tail current data plotted as a function of test pulse potential (voltage
protocol, upper panel) in the absence and presence of 25 nM BeKm-1. Current data for each cell are normalised to maximal tail current under
control conditions (n=11 cells). Data were ¢tted using a Boltzmann equation (solid lines). B: Mean fractional block of IHERG tails plotted as a
function of test voltage. C: Representative IHERG traces (upper panel) in response to a modi¢ed long-pulse protocol with an additional 4 s step
to +80 mV (lower panel). Experiments were performed as in Fig. 2E (i.e. measuring ¢rst sweep after equilibration in toxin). D: Mean
(S S.E.M.) fractional block data obtained using this modi¢ed long-pulse protocol (n=6 cells). E: Mean data from an identical experiment per-
formed with 10 nM ergtoxin, in which re-development of block after the step from +80 mV to 0 mV never occurs. Intermittent lines in D and
E indicate fractional block during the long-pulse protocol re-drawn from Fig. 2F. F: E¡ect of ‘mid-pulse’ application of either BeKm-1 or erg-
toxin during a 10 s depolarising step from 380 mV to 0 (see inset). Arrows indicate the timing of the rapid solution switch from normal Ty-
rode’s solution to normal Tyrode’s containing the respective toxin. Mean fractional blockSS.E.M. (n=3 cells in each group) is plotted as a
function of time, with time zero corresponding to the depolarisation from 380 mV to 0.
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HERG channels would be expected to be in the inactive state,
and these data, therefore, support the idea that BeKm-1 does
not primarily bind to the inactive channel state. Thus, the
data are concordant with the potency of blockade for di¡erent
channel states being closeds openEinactivated. However,
we are not able to exclude the possibility that the attenuation
of blockade observed at +80 mV may involve a voltage-in-
duced conformational change that is independent of inacti-
vation. Similar observations were made in two cells with
rBeKm-1 (data not shown).
Similar experiments using 10 nM ergtoxin are shown in
Fig. 3E. As with BeKm-1, depolarisation to +80 mV during
the long pulse resulted in decreased block in the presence of
ergtoxin; this is consistent with the ¢ndings of Gurrola et al.
[31]. However, unlike BeKm-1, ergtoxin block did not re-de-
velop on repolarisation from +80 mV to 0 (ANOVA,
Ps 0.75). This characteristic of ergtoxin action has not been
previously reported. The ability of BeKm-1 block of IHERG to
re-develop on repolarisation from +80 mV to 0, as inactiva-
tion is relieved and channels cycle back to the open state,
suggests that BeKm-1 can also bind and block the open state
channel, while ergtoxin does not. This may indicate that erg-
toxin, in comparison with BeKm-1, has a mechanism of block
more dependent on interacting with the closed state.
However, as depolarisation in the presence of ergtoxin does
reveal the presence of some channel blockade (albeit one that
diminishes with time), ergtoxin must ^ at least initially upon
depolarisation ^ be able to block channels that have attained
the open state. One possible explanation for this phenomenon
is that ergtoxin can enter and remain in a blocking conforma-
tion with closed but not open HERG channels, although there
is a time delay for ergtoxin’s blockade to diminish when
closed channels blocked by ergtoxin switch to the open con-
formation upon depolarisation. To test this, and thus deter-
mine whether ergtoxin and BeKm-1 di¡er in their ability to
block open channels, experiments were performed in which
each toxin was rapidly superfused onto the cells during the
course of a depolarising pulse. Cell membrane potential was
depolarised to 0 mV for 10 s, but the particular toxin was not
added until 2 s after the beginning of the depolarisation (see
Fig. 3F). Rapid superfusion of 25 nM BeKm-1 onto cells
during depolarisation led to HERG blockade (V23S 1%,
which is of similar magnitude to that seen at the end of de-
polarisations in Fig. 2F), suggesting that BeKm-1 can block
HERG channels in the open state. However, rapid superfu-
sion of 10 nM ergtoxin onto cells during depolarisation did
not lead to blockade (V2S 1%), suggesting that ergtoxin can-
not block HERG channels in the open state, except when the
toxin has been previously allowed to interact with channels in
the closed state. Considering the data presented concerning
inverse time- and voltage-dependent block, these ¢ndings are
concordant with ergtoxin’s state dependence of blockade
being closedFopenv inactivated. However, as for BeKm-
1, it is feasible that alternative conformational changes inde-
pendent of inactivation could contribute to the rapid diminu-
tion of ergtoxin block upon depolarisation to +80 mV.
3.5. Frequency- and use-dependence of BeKm-1 block of IHERG
Collectively, the data in Figs. 2 and 3 suggest that BeKm-1
inhibits IHERG by a mechanism that includes closed channel
state blockade. Further to this, we investigated frequency- and
use-dependence of block. A voltage protocol was applied with
three di¡erent start-to-start (S-to-S) intervals (1.5, 3 and 24 s)
and the degree of IHERG tail block compared between them.
Under control conditions, applying this protocol at these
varying frequencies had no statistically signi¢cant e¡ect on
IHERG tail amplitude (n=5 cells, ANOVA, P=0.99). For
each cell, after a steady-state baseline was achieved in control
Fig. 4. Frequency- and use-dependent inhibition of IHERG by
BeKm-1. A: Representative current records from a cell in the pres-
ence of 25 nM BeKm-1, using a voltage protocol (lower panel) ap-
plied with three di¡erent S-to-S intervals. Numbers in parentheses
correspond to pulse numbers in B; for this cell the peak tail current
in control solution (not shown) was 3.5 nA. B: Mean fractional
block of IHERG tails. The protocol was applied with a S-to-S inter-
val of 1.5 s to reach steady state in the absence of toxin. 25 nM
BeKm-1 was then applied and the protocol repeated ¢rst with a
S-to-S of 1.5 s (pulses 1^5) followed by 3 s (6^10) and ¢nally 24 s
(11^15). Arrows indicate changes in S-to-S interval. HERG channel
block decreased with increased frequency of stimulation (ANOVA,
P6 0.001). C: Use-dependent changes of BeKm-1 block of IHERG
tails. Cells were equilibrated in 25 nM BeKm-1 while held at 380
mV prior to being subjected to the same voltage command as in A
applied at three di¡erent S-to-S intervals. Pulse 1 corresponds to the
¢rst pulse in BeKm-1. Fractional block was calculated relative to
the corresponding control pulse in the absence of BeKm-1. Steady-
state BeKm-1 block was smaller at higher stimulation rates (AN-
OVA, P6 0.0001).
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solution, 25 nM BeKm-1 was applied and allowed to equili-
brate at the 380 mV holding potential, and then stimulation
was resumed at the highest frequency (pulse number 1, Fig.
4B). The S-to-S interval was then increased to 3 s and ¢nally
24 s (indicated by arrows). Representative currents in the
presence of toxin recorded in the same cell are shown in
Fig. 4A, corresponding to pulses numbered 5, 10 and 15 of
mean data in Fig. 4B. For the ¢nal time point at each fre-
quency, HERG channel fractional block was signi¢cantly
greater at slower stimulation frequencies (ANOVA with a
Bonferroni post-test, P6 0.001). Use-dependence of BeKm-1
block was investigated using a voltage protocol identical to
that shown in Fig. 4A applied at S-to-S intervals of 1.5, 3 and
24 s. Cells were paced at the respective frequency in the ab-
sence of BeKm-1, then allowed to equilibrate in 25 nM
BeKm-1. Cells were then paced again at the same rate in
the presence of BeKm-1 to study use-dependent changes of
block. Fractional block was calculated relative to the corre-
sponding pulse in control (Fig. 4C). Two-way ANOVA
showed main e¡ects for both frequency and pulse number
(P6 0.0001 for each), replicating the frequency dependence
e¡ects in Fig. 4B; analysis of data from each frequency
showed signi¢cant use-dependent e¡ects for 1.5 s S-to-S (AN-
OVA, P=0.0004), but not for 3 s (P=0.52) or 24 s (P=0.99).
Overall, the inverse frequency- and reverse use-dependent data
are concordant with the notion that BeKm-1 employs a pref-
erential closed state mechanism in blocking HERG.
3.6. Conclusions
We have demonstrated a new method for the synthesis of
functional BeKm-1. Under similar experimental conditions,
synthesised BeKm-1 blocked IHERG with identical potency to
that of the commercially available rBeKm-1. BeKm-1 block-
ade of HERG varies inversely with temperature, time, voltage,
use and frequency, and this has not been shown before for
this or any other HERG blocking compound. BeKm-1, there-
fore, provides a striking example of an agent for which the
degree of HERG blockade varies markedly depending upon
the electrophysiological protocols (e.g. S-to-S interval) and
conditions (e.g. temperature) used. The data suggest that the
blockade is preferentially closed channel state-dependent, with
a component of open, but not inactive, state-dependent block-
ade, and this is di¡erent from the mechanism of blockade by
ergtoxin. This adds further weight to the argument that some
blockers of HERG may act by a mechanism (and possibly at
a site) distinct from the open state-dependent mechanism oc-
curring at the high a⁄nity site described within the vestibule
[6], and future work will focus on whether such a site might
play a role in HERG blockade by some drugs (as opposed to
peptide toxins).
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